Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Midazolam(placebo) Clear all
Terminated Phase 2 Interventional Results available

Nitrous Oxide for PTSD

NCT04378426
View directory record Official record
Conditions
PTSD
Interventions
Nitrous Oxide, Midazolam, Nitrogen, Oxygen, Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

NCT04110535
View directory record Official record
Conditions
Abuse, Drug
Interventions
Remimazolam, Midazolam, Saline
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

NCT04586920
View directory record Official record
Conditions
Healthy
Interventions
LY3509754, Placebo, Itraconazole, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Anaheim, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)

NCT00894465
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
midazolam, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 6 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Ketamine in Borderline Personality Disorder

NCT03395314
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Midazolam in Children as a Pre-Operative Sedative

NCT02314546
View directory record Official record
Conditions
Sedation, Conscious
Interventions
Midazolam, xylocaine, saline placebo
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Months to 7 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

NCT06177457
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07293893, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Withdrawn Phase 4 Interventional

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

NCT03226080
View directory record Official record
Conditions
Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
Interventions
Rocuronium, Sugammadex, Normal saline
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Not applicable Interventional Results available

Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain

NCT00720330
View directory record Official record
Conditions
Pain, Nausea
Interventions
ropivacaine, Lidocaine/Ketamine, placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Alternative Sedation During Bronchoscopy

NCT01158820
View directory record Official record
Conditions
Sedation
Interventions
Dexmedetomidine load, Ketamine load, Midazolam load, Fentanyl load, Dexmedetomidine maintenance, Ketamine maintenance, Midazolam demand, Fentanyl demand, Benadryl demand
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01757756
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
Pf-05175157, placebo, midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time

NCT02620501
View directory record Official record
Conditions
Dysphagia, GERD, Abdominal Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional

Ketamine for Pain Control After Severe Traumatic Injury

NCT04274361
View directory record Official record
Conditions
Hospital Inpatient Trauma Injury, Pain Management
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 64 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Garlic Supplements on Opioids in Healthy Volunteers

NCT00499460
View directory record Official record
Conditions
Healthy, No Evidence of Disease
Interventions
garlic powder tablets, oxycodone
Dietary Supplement · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory

NCT00142493
View directory record Official record
Conditions
Memory Losses, Amnesia-Memory Loss
Interventions
Propofol, Thiopental Sodium, Dexmedetomidine Hydrochloride, Midazolam Hydrochloride, placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4268989 (MORF-057) in Healthy Participants

NCT06964776
View directory record Official record
Conditions
Healthy
Interventions
LY4268989, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional

Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

NCT01791296
View directory record Official record
Conditions
Sleep Deprivation, Delirium
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
Maisonneuve-Rosemont Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional Results available

Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety

NCT00928772
View directory record Official record
Conditions
Anxiety
Interventions
CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM, MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY, NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED
Device · Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
50 Years to 90 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 25, 2026, 10:15 AM EDT